Investigating how specific protein interactions affect blood cancer development
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms
This study is looking at a specific pathway in cancer to find new ways to treat myeloproliferative neoplasms (MPN) by targeting certain protein interactions, which could lead to better treatments that help manage the disease without affecting all the good functions of the proteins involved.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10883645 on NIH RePORTER |
What this research studies
This research focuses on understanding the Ras/MAPK signaling pathway, which is involved in many cancers, including myeloproliferative neoplasms (MPN). The researchers aim to develop new treatment strategies that target specific protein interactions rather than the active sites of kinases, which have proven ineffective. By identifying how different substrate binding domains of the ERK2 protein influence cancer progression, they hope to create therapies that can better control disease advancement. This approach may lead to more effective treatments that preserve some kinase functions while inhibiting harmful ones.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms or related blood cancers.
Not a fit: Patients with cancers not driven by the Ras/MAPK pathway may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with myeloproliferative neoplasms and potentially other cancers.
How similar studies have performed: While targeting the Ras/MAPK pathway has been challenging, this novel approach of focusing on substrate interactions has not been widely tested, making it a potentially groundbreaking strategy.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Wiest, David L. — Research Inst of Fox Chase Can Ctr
- Study coordinator: Wiest, David L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.